高级检索
当前位置: 首页 > 详情页

REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY Twelve-Month Results From the LUMINOUS Study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Camden Med Ctr, Singapore, Singapore [2]Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China [3]Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China [4]Nihon Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan [5]Japanese Red Cross Nagasaki Genbaku Hosp, Nagasaki, Japan [6]Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Kyeonggi, South Korea [7]Hosp Selayang, Dept Ophthalmol, Lebuhraya Selayang Kepong, Batu Caves, Selangor, Malaysia [8]Novartis Pharma AG, Basel, Switzerland
出处:
ISSN:

关键词: visual acuity central retinal thickness effectiveness LUMINOUS neovascular age-related macular degeneration polypoidal choroidal vasculopathy ranibizumab real-world outcomes safety vascular endothelial growth factor

摘要:
Purpose: To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). Methods: Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. Results: At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 12 in the PCV and non-PCV groups was +5.0 and +3.0 letters, respectively; these gains were achieved with a mean of 4.4 and 5.1 ranibizumab injections. Eighty percent of PCV patients and 72.2% of non-PCV patients who had baseline visual acuity >= 73 letters maintained this level of vision at Month 12; 20.6% and 17.9% of patients with baseline visual acuity <73 letters achieved visual acuity >= 73 letters in these groups. Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group. The rate of serious ocular adverse events was 0.7% (PCV group) and 0.9% (non-PCV group). Conclusion: LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 眼科学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 眼科学
JCR分区:
出版当年[2018]版:
Q1 OPHTHALMOLOGY
最新[2024]版:
Q2 OPHTHALMOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Camden Med Ctr, Singapore, Singapore [*1]13-03 Camden Med Ctr,1 Orchard Blvd, Singapore 248649, Singapore
通讯作者:
通讯机构: [1]Camden Med Ctr, Singapore, Singapore [*1]13-03 Camden Med Ctr,1 Orchard Blvd, Singapore 248649, Singapore
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study [2]Differentially Regulated Apolipoproteins and Lipid Profiles as Novel Biomarkers for Polypoidal Choroidal Vasculopathy and Neovascular Age-Related Macular Degeneration [3]LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY [4]Long-term Outcomes of Neovascular Age-related Macular Degeneration Treated with As Needed Anti-Vascular Endothelial Growth Factor Agents [5]Comparison of choriocapillary flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration [6]Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration A MOOSE-compliant meta-analysis [7]Comparison of cytokine levels in the aqueous humor of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration patients [8]Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation [9]HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION [10]Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial

资源点击量:28518 今日访问量:0 总访问量:1589 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)